Results of the CALGB 40502 Study in TNBC
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer, a randomized phase III trial of paclitaxel compared with nab-paclitaxel or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer.<br />
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC), a randomized phase III trial of paclitaxel compared with nab-paclitaxel (Abraxane) or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
There were a few noteworthy findings in the updated results reported at the 2017 San Antonio Breast Cancer Symposium, Carey notes. The original finding of an improvement in progression-free survival with paclitacel or nab-paclitaxel over ixabepilone held true, and this translated into an overall survival advantage.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
